General
Preferred name
VERATRAMINE
Synonyms
NSC17821 ()
NSC23880 ()
NSC 17821, NSC 23880 ()
P&D ID
PD011936
CAS
60-70-8
Tags
available
Structure
Probe scores
P&D probe-likeness score
[[ v.score ]]%
Structure formats
[[ format ]]
[[ compound[format === 'MOL' ? 'molblock' : format.toLowerCase()] ]]
Description
(extracted from source data)
DESCRIPTION Veratramine (NSC17821; NSC23880) is an orally active inhibitor of the PI3K/Akt/mTOR signaling pathway and a SIGMAR1 modulator. Veratramine induces autophagic apoptosis of tumor cells, arrests the cell cycle at the G0/G1 phase, and inhibits epithelial-mesenchymal transition (EMT)-related proteins to reduce tumor migration. Veratramine reduces spinal cord and sciatic nerve pathological damage in a neuropathy model by inhibiting SIGMAR1 binding to NMDAR and phosphorylation of NMDAR Ser896. Veratramine has anti-tumor proliferation, apoptosis induction, anti-inflammatory and neuroprotective activities, and can be used in the study of cancers such as liver cancer and osteosarcoma, as well as diabetic peripheral neuropathy[1][2][3][4].
PRICE 33
DESCRIPTION Veratramine (NSC-23880)(NSC-17821; NSC-23880) is a potent signal transduction inhibitor for treating tumors. (TargetMol Bioactive Compound Library)
Compound Sets
4
Cayman Chemical Bioactives
11724
MedChem Express Bioactive Compound Library
HY-N0837
Selleckchem Bioactive Compound Library
veratramine
TargetMol Bioactive Compound Library
T3364
External IDs
22
Properties
(calculated by RDKit )
Molecular Weight
409.3
Hydrogen Bond Acceptors
3
Hydrogen Bond Donors
3
Rotatable Bonds
2
Ring Count
5
Aromatic Ring Count
1
cLogP
4.59
TPSA
52.49
Fraction CSP3
0.7
Chiral centers
8.0
Largest ring
6.0
QED
0.63
Structural alerts
0
No structural alerts detected
Related compounds
Custom attributes
(extracted from source data)
Target
Sodium Channel
Akt
Apoptosis
Autophagy
MTOR
PI3K
Pathway
Membrane Transporter/Ion Channel
PI3K/Akt/mTOR
Source data